Estimating the global impact of rotavirus vaccines on child mortality.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 14 08 2023
revised: 22 09 2023
accepted: 05 10 2023
medline: 4 12 2023
pubmed: 21 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

We estimated the global impact of rotavirus vaccines on deaths among children under five years old by year. We used a proportionate outcomes model with a finely disaggregated age structure to estimate rotavirus deaths prevented by vaccination over the period 2006-2019 in 186 countries. We ran deterministic and probabilistic uncertainty analyses and compared our estimates to surveillance-based estimates in 20 countries. We estimate that rotavirus vaccines prevented 139,000 under-five rotavirus deaths (95% uncertainty interval 98,000-201,000) in the period 2006-2019. In 2019 alone, rotavirus vaccines prevented 15% (95% uncertainty interval 11-21%) of under-five rotavirus deaths (0.5% of child mortality). Assuming global use of rotavirus vaccines and coverage equivalent to other co-administered vaccines could prevent 37% of under-five rotavirus deaths (1.2% of child mortality). Our estimates were sensitive to the choice of rotavirus mortality burden data and several vaccine impact modeling assumptions. The World Health Organization's recommendation to remove age restrictions in 2012 could have prevented up to 17,000 rotavirus deaths in the period 2013-2019. Our modeled estimates of rotavirus vaccine impact were broadly consistent with estimates from post-vaccination surveillance sites. Rotavirus vaccines have made a valuable contribution to global public health. Enhanced rotavirus mortality prevention strategies are needed in countries with high mortality in under-5-year-old children.

Identifiants

pubmed: 37863311
pii: S1201-9712(23)00742-7
doi: 10.1016/j.ijid.2023.10.005
pmc: PMC10689250
pii:
doi:

Substances chimiques

Rotavirus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-97

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Bill & Melinda Gates Foundation
ID : INV-007381
Pays : United States

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of competing interest The authors have no competing interests to declare.

Références

Clin Infect Dis. 2016 May 1;62 Suppl 2:S96-S105
pubmed: 27059362
PLoS One. 2017 Sep 11;12(9):e0183392
pubmed: 28892480
Lancet Glob Health. 2019 Nov;7(11):e1541-e1552
pubmed: 31607466
Lancet Child Adolesc Health. 2022 Feb;6(2):106-115
pubmed: 34800370
Lancet. 2009 May 2;373(9674):1543-9
pubmed: 19303633
J Infect Dis. 2020 Oct 13;222(10):1731-1739
pubmed: 32095831
Expert Rev Vaccines. 2020 Jun;19(6):585-593
pubmed: 32543244
Vaccine. 2017 Oct 13;35(43):5835-5841
pubmed: 28941619
Lancet Infect Dis. 2019 Jul;19(7):717-727
pubmed: 31178289
Lancet Glob Health. 2020 Sep;8(9):e1195-e1202
pubmed: 32827481
Clin Infect Dis. 2019 Aug 30;69(6):1071-1078
pubmed: 30689799
EClinicalMedicine. 2022 Oct 06;54:101687
pubmed: 36247922
JAMA Netw Open. 2018 Aug 3;1(4):e181579
pubmed: 30646127
PLoS One. 2017 Nov 3;12(11):e0187446
pubmed: 29099848
J Glob Health. 2019 Dec;9(2):020801
pubmed: 31673345
Vaccine. 2022 Nov 2;40(46):6631-6639
pubmed: 36210251
Vaccine. 2013 Dec 16;31(52):6170-1
pubmed: 23746456
Infect Dis Poverty. 2016 Aug 12;5(1):83
pubmed: 27514855
Am J Trop Med Hyg. 2018 Apr;98(4):1197-1201
pubmed: 29436336
Elife. 2021 Jul 13;10:
pubmed: 34253291

Auteurs

Andrew Clark (A)

Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: andrew.clark@lshtm.ac.uk.

Sarwat Mahmud (S)

Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Frederic Debellut (F)

PATH, Geneva, Switzerland.

Clint Pecenka (C)

PATH, Seattle, WA, USA.

Mark Jit (M)

Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; Modelling and Economics Unit, Public Health England, London, UK.

Jamie Perin (J)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.

Jacqueline Tate (J)

Centers for Disease Control and Prevention, Atlanta, USA.

Heidi M Soeters (HM)

World Health Organization, Geneva, Switzerland.

Robert E Black (RE)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.

Mathuram Santosham (M)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.

Colin Sanderson (C)

Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH